Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 12/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644667 | 0.90 | L3MBTL1 (0.41) | L3MBTL1DUTCRBN | |
| SCHEMBL16632528 | 0.83 | L3MBTL1 (0.43) | L3MBTL1DUTCRBNKMT2AKDM4E | |
| SCHEMBL16632625 | 0.82 | L3MBTL1 (0.42) | L3MBTL1DUTKMT2A | |
| SCHEMBL16632594 | 0.82 | L3MBTL1 (0.48) | L3MBTL1DUTALDH1A1KMT2AMAPT | |
| SCHEMBL16632579 | 0.81 | L3MBTL1 (0.41) | L3MBTL1DUTCRBNALDH1A1KMT2A | |
| SCHEMBL16632486 | 0.78 | L3MBTL1 (0.53) | L3MBTL1DUT | |
| SCHEMBL16632917 | 0.76 | L3MBTL1 (0.42) | L3MBTL1DUTCRBNKMT2A | |
| SCHEMBL16632604 | 0.76 | L3MBTL1 (0.42) | L3MBTL1DUTALDH1A1MAPT | |
| SCHEMBL16632490 | 0.74 | L3MBTL1 (0.44) | L3MBTL1DUTKMT2AMAPT | |
| SCHEMBL16632698 | 0.74 | L3MBTL1 (0.53) | L3MBTL1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885DUT 19/4885CRBN 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.